



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

CREATE CHANGE


MODULE 1 | GENETIC MAPPING

Session 8. Meta-analysis

7th July 2025

- Sample size is a key consideration in GWAS
- Small samples have low power to detect associations, particularly at the genome-wide significance threshold of $P < 5 \times 10^{-8}$
- So, how can we derive information from small GWAS? One option is to combine association results across studies. This process is called meta-analysis.
- As we will see in this lecture, there are several advantages of using meta-analysis in genomics research, but there are also important considerations to be taken


- Consider this toy example.
What would you conclude from these results?
- What if we add information from an independent study, with the same number of participants and same effect estimates?



Based on this study, there is no evidence that the variant is associated with the trait studied


- Consider this toy example. What would you conclude from these results?
- What if we add information from an independent study, with the same number of participants and same effect estimates?

Study	N	Estimate	SE	P
Study 1	1000	-0.47	0.4333	0.278
Study 2	1000	-0.47	0.4333	0.278
Summary	2000	-0.47	0.3064	0.125




The added evidence increased confidence in the estimate, but error is still large

- Consider this toy example. What would you conclude from these results?
- What if we add information from an independent study, with the same number of participants and same effect estimates?



With a 3rd study added the error of the estimate decreases further, and the probability of seeing this effect by chance (i.e. if there is no true effect in the population) is smaller

- Consider this toy example. What would you conclude from these results?
- What if we add information from an independent study, with the same number of participants and same effect estimates?
- Note that the point estimate did not change, only its precision
- This is an extreme example. In real life we see \neq estimates across studies with \neq SEs, depending on the real effect in the population.



With a 4th study added the P-value is now nominally significant

What are key advantages of using meta-analysis in genomics research?

1. Increase statistical power

As we saw in the toy example, small studies may have insufficient power to identify true genetic effects. However, combining information from independent studies can improve precision of the effect estimates. This is particularly relevant when it comes to detecting subtle genetic effects.

2. Increase sample size without sharing individual-level data

Sharing individual-level genetic data across research groups raises privacy concerns. Meta-analyses overcome those issues and other ethical considerations by relying solely on summary statistics.

3. Identify heterogeneity across studies

Meta-analysis provide the opportunity to investigate potential sources of heterogeneity (e.g., study design, population characteristics, or genotyping methods).

4. Resolving inconsistent findings

Inconsistent or contradictory results across individual studies can be explored through meta-analysis. Meta-analysis can help identify the sources of discrepancies, evaluate the overall effect size, and provide a more accurate assessment of the true association.

Meta analysis approaches:

- The basic idea of meta-analysis in GWAS is to calculate a 'weighted mean' per SNP

Q: How do we weight each study?

1. Fixed-effect model

assumes that the one true effect of SNP across studies, differences between studies due to sampling error only.

The 'combined effect' is the estimate of the true effect.

2. Random-effects model

assumes that the true effect across studies is sampled from a normal distribution; differences between studies due to sampling error within a study, plus differences (heterogeneity) between studies. There are two sources of variance – within study plus between study variance

The 'combined effect' is the mean of the normal distribution.

Most common approach is a fixed effect model using an **inverse-variance weighted method**:

- Estimates from each study are weighted by the inverse of the variance of the effect estimate ($1/SE^2$)
- Larger studies (with smaller SEs) are given more weight

Fixed-effect model

$$\beta = \frac{\text{sum of (estimate} \times \text{weight)}}{\text{sum of weights}} = \frac{\sum_i \beta_i w_i}{\sum_i w_i} \quad se = \sqrt{\frac{1}{\sum_i w_i}}$$

β_i : effect estimate for study i
 w_i : weight for study i , given as $\frac{1}{se_i^2}$
 se_i : standard error for study i

- If all the weights are the same, the weighted average is equal to the mean effect
- The standard error can be used to derive:
 - confidence interval: measure of precision (or uncertainty) of the summary estimate
 - P-value: measure of strength of the evidence against the null hypothesis of no effect

Some important considerations for GWAS meta-analyses

1. Trait definition

Ideally, trait definitions should be the same across studies and same covariates adjustments used. Similarly, it is important to consider any data transformations (scale of the effects).

2. Quality checks

Have individual studies used appropriate QC (e.g. Hardy-Weinberg equilibrium, genotype missing rate, imputation scores)?

3. Heterogeneity

Heterogeneity in effect size estimates may come from several sources. Phenotype variability may cause heterogeneity and may result in spurious associations. Heterogeneity due to ancestry can occur given differences in LD with true causal variants. Other differences between studies (e.g. genotyping platforms, imputation software, QC, etc.) can also introduce heterogeneity.

4. Independence of the samples

It is very important to consider if there is any relatedness between participants across studies as this can bias results.

Links for further reading

- [Cochrane Training Chapter 10: Analysing data and undertaking meta-analyses](#)
- [Doing Meta-Analysis with R: A Hands-On Guide](#)
- [Evangelou et al. 2013 Nat Rev Genet](#)
- [Zeggini 2009 Pharmacogenomics](#)